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ABSTRACT 
Pre-Menstrual Syndrome (PMS) is defined as the recurrence of psychological and physical symptoms in the luteal phase, which remit 
in the follicular phase of the menstrual cycle. Symptoms of which fall in three domains: Emotional, Physical and Behavioural, eg: 
depression, irritability, tension, crying, abdominal cramps, fatigue, bloating, food cravings, poor concentration, social withdrawal 
etc. Premenstrual symptoms can be managed if diagnosed at right time with suitable pharmacological and non pharmacological 
treatment. Therefore it is suggested that life style modification & counselling are essential. If neglected, may even be life 
threatening in patients with severe symptoms can be occur. Non-pharmacologic interventions for PMS include patient education, 
supportive therapy, and behavioural changes. Behavioural measures include keeping a symptom diary, getting adequate rest and 
exercise, and making dietary changes. Dietary supplements in women with PMS should include vitamins (A, E and B6), calcium, 
magnesium, multivitamins/mineral supplements and evening primrose oil. Pharmacological treatment includes anti-depressants and 
hormonal therapy. Surgery may be considered in severely affected patients who fail to respond to other therapies and also have 
significant gynaecologic problems for which surgery would be appropriate.  
Keywords: Pre-Menstrual Syndrome, Management of pre-menstrual syndrome, dysmenorrhoea. 
 
INTRODUCTION 
enstruation is a periodic discharge through the 
vagina, a bloody secretion containing tissue 
debris from the shedding of endometrium from 
the non-pregnant uterus. The average duration of 
menstruation is 4 to 5 days, and it recurs at 
approximately 28-day intervals throughout the 
reproductive life of non-pregnant women. Premenstrual 
syndrome (PMS) is defined as the recurrence of 
psychological and physical symptoms in the luteal phase 
(7 to 14 days prior to menstruation), which remit in the 
follicular phase of the menstrual cycle1. Symptoms of 
which fall in three domains: emotional, physical and 
behavioural. The most common emotional and mood-
related symptoms of PMS include depression, irritability, 
tension, crying, over sensitivity (hypersensitivity), and 
mood swings with alternating sadness and anger2. 
Physical discomforts include abdominal cramps, fatigue, 
bloating, and breast tenderness (mastalgia), acne and 
weight gain. Behavioural symptoms include food cravings, 
poor concentration, social withdrawal, forgetfulness and 
decreased motivation3. Despite considerable research, 
causes of PMS remain enigmatic and the exact causes of 
PMS are not clearly understood but have been attributed 
to hormonal changes, neurotransmitters, prostaglandins, 
diet, drugs, and lifestyle4, 5. Several descriptive studies 
state that premenstrual symptoms associated with 
premenstrual syndrome (PMS) may impair the overall 
physical health of a woman as well as interpersonal 
relationships, daily routine, and work productivity6. As per 
previous studies, in India the prevalence of PMS is 20% of 
which 8% suffer with severe symptoms. It has also been 
reported by the same group of authors that 10% of the 
sufferers were found to have suicidal ideas 7. There are 
reports stating that the severity of  PMS can hamper the 
daily activities that can even lead to suicidal tendency, it 
is essential that awareness should be given to  the young 
females  for managing the issues by pharmacological and 
non pharmacological methods, to improve the quality  of 
life. 
MANAGEMENT 
Key aspects in the diagnosis and management of women 
presenting with premenstrual symptoms include detailed 
history-taking, prospective diary recording of symptoms 
and the exclusion of other significant medical and 
psychiatric disorders in order to allow a clear diagnosis to 
be made. Treatment strategies are driven by symptom 
severity but for most women both pharmacological and 
non-pharmacological approaches are required. Initially, 
all patients with PMS should be offered non-
pharmacologic therapy8.Medication should be offered to 
patients with persistent symptoms of PMS and those who 
meet criteria for Pre menstrual Dysphoric Disorder 
(PMDD).  
NON-PHARMACOLOGIC THERAPY 
Non-pharmacological interventions for PMS include 
patient education, supportive therapy, and behavioural 
changes 9, 10. Several studies state that Women who have 
been educated about the biologic basis and prevalence of 
PMS report an increased sense of control and relief of 
symptoms 11. A prospective survey study on premenstrual 
syndrome in young and middle aged women with an 
emphasis on its management states that life style 
modifications in the form of yoga, meditation, positive 
coping techniques & exercises are helpful in management 
Pre Menstrual Syndrome: Different Approaches of Management
M
Review Article 
Int. J. Pharm. Sci. Rev. Res., 27(1), July – August 2014; Article No. 66, Pages: 361-366                                                            ISSN 0976 – 044X 
 
 
International Journal of Pharmaceutical Sciences Review and Research 
Available online at www.globalresearchonline.net  
© Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited. 
 
362 
of mild symptoms along with dietary supplements in the 
form of calcium, vitamin B6 & soy isoflavones. Counselling 
the victims & relatives is more essential so that sufferers 
gain adequate care and attention and it also help them to 
overcome the incidence 12. Behavioural measures include 
keeping a symptom diary, getting adequate rest and 
exercise, and making dietary changes. 
The daily symptom diary may help patients identify 
optimal times for implementing behavioural and other 
changes to manage symptom exacerbations. Maintaining 
a symptom diary helps them to manage PMS or PMDD 13. 
Sleep disturbances, ranging from insomnia to excessive 
sleep, are common in women with PMS. A structured 
sleep schedule with consistent sleep and wake times is 
recommended, especially during the luteal phase 8. 
Dietary restrictions and exercise may also be useful in 
patients with PMS 8, 14. Sodium restriction has been 
proposed to minimize bloating, fluid retention, and breast 
swelling and tenderness. Caffeine restriction is 
recommended because of the association between 
caffeine and premenstrual irritability and insomnia. 
Dietary restrictions are often recommended to alleviate 
the physical and psychological symptoms of PMS. The 
most common dietary recommendations are to restrict 
sugar and increase consumption of complex 
carbohydrates 15. Women who consume a carbohydrate-
rich beverage daily during the late luteal phase 
experienced mood changes when compared with the 
women who consumed an iso-caloric beverage. 
PMS patients consume 275% more refined sugar, 62% 
more refined carbohydrates, 78% more sodium, 79% 
more dairy products, 52% less zinc, 77% less magnesium 
and 53% less iron than women without PMS has been 
noted between saturated, but not unsaturated, fats in the 
diet and blood oestrogens levels. Furthermore, women 
who derive approximately 20% of their calories from fat 
have significantly lower blood oestrogens levels than 
women who consumed 40% of their calories as fat 13. 
Certain studies state that Women who consume large 
amounts of caffeine are more likely to suffer from PMS. 
Aerobic exercise 
Women who have PMS are often encouraged to increase 
their activity level. In certain prospective control studies, 
it has been hypothesized that exercise (particularly 
aerobic varieties) increases endorphin levels, which in 
turn improves mood15. Several descriptive studies indicate 
that women who exercise regularly have fewer PMS 
symptoms than sedentary women. Given the associated 
benefits of exercise, it seems reasonable to recommend 
an aerobic exercise program to help alleviate PMS 
symptoms15, 16. 
Cognitive Behaviour Therapy 
Cognitive behaviour therapy uses psychotherapy 
techniques that focus on modifying problematic thoughts, 
emotions, and behaviours. It appears to be effective for 
other affective and somatic disorders such as anxiety and 
pain; thus, it theoretically could be useful for PMS 
treatment. 
DIETARY SUPPLEMENTATION 
Dietary supplements in women with PMS should include 
vitamins (A, E, and B6), calcium, magnesium, 
multivitamin/mineral supplements, and evening primrose 
oil13.  
Pyridoxine (vitamin B6)  
Pyridoxine, or vitamin B6, is one of the most widely used 
and it is the most probable controversial treatment for 
PMS. Vitamin B6 is believed to correct a deficiency in the 
hypothalamic-pituitary axis. Vitamin B6 is a cofactor in 
the synthesis of tryptophan and tyrosine, which are the 
precursors of serotonin and dopamine, respectively. 
Theoretically, low levels of vitamin B6 lead to high levels 
of prolactin that in turn produce the oedema and 
psychological symptoms associated with PMS. Vitamin B6 
can also cause substantial toxicity and unpleasant side 
effects. In a Randomized Control Trial, A Jacob et al states 
that Taken at doses as low as 500 mg daily, it can produce 
a progressive sensory ataxia and can also cause 
gastrointestinal side effects, particularly nausea17. A daily 
dose of 200-600 mg, VitaminB6 lowers serum oestrogen 
and elevates serum progesterone levels. This shift should 
benefit to those patients who have an elevation of 
oestrogen in relation to progesterone. The active form of 
pyridoxine, pyridoxal-5-phosphate, is a co-factor in the 
formation of the following neurotransmitters; dopamine, 
serotonin and GABA. Deficiencies of each of these 
neurotransmitters have been implicated in some 
symptoms of PMS, particularly depression 18. 
Evening primrose oil 
Evening primrose oil is used extensively to alleviate PMS 
symptoms. Evening primrose oil contains two essential 
fatty acids: linoleic and γ-linolenic. Some experts suggest 
that women with PMS are deficient in γ-linolenic acid, 
which is necessary for prostaglandin formation. Evening 
primrose oil is generally well tolerated, but occasionally it 
can produce nausea, dyspepsia, and headache. Long-term 
use can be associated with increased risk of inflammation, 
thrombosis, and immunosuppression. Finally, evening 
primrose oil is relatively expensive 19. 
Magnesium 
Magnesium supplementation seems to be correcting a 
deficiency. Magnesium status of women with PMS to 
asymptomatic subjects have no relationship between 
serum levels of magnesium and premenstrual symptoms 
but have a significant decrease in Red Blood Cell 
magnesium levels in PMS patients. A magnesium 
deficiency causes a depletion of brain dopamine. A 
deficiency may also cause hyperplasia of the adrenal 
cortex, elevating aldosterone and contributing to fluid 
retention. A vicious cycle results as the elevated 
aldosterone may in turn increase urinary excretion of 
magnesium. A magnesium deficiency may also interfere 
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with essential fatty acid metabolism, as magnesium is 
necessary for conversion of cis-linoleic to gamma linolenic 
acid. In certain descriptive studies, Magnesium plays an 
integral part in all activities of pyridoxine, being necessary 
for its phosphorylation, the first step in conversion to PLP. 
High lead levels have been implicated in PMS, magnesium 
provides benefit by blocking intestinal absorption of 
lead20. 
Vitamin E 
The research first focused upon the effect of vitamin E in 
alleviating breast symptoms. In a double-blind study there 
was a significant decrease in some symptoms 19. The 
physiological mechanisms for vitamin E in the treatment 
of PMS are not clearly understood. Vitamin E has a role in 
the modulation of prostaglandin synthesis. Tocopherol 
reduces release of arachidonic acid from phospholipids, 
resulting in a decrease in formation of PGE2, or 
inflammatory prostaglandins. Alpha-tocopherol, which 
crosses the blood-brain barrier, also has modulating 
effects on neurotransmitters. Supplementation of vitamin 
E, for instance, blocks arachidonic acid, induced decrease 
in GABA. In the study doses of 150-300 IU D,L-alpha-
tocopherol twice daily succeeded in significantly reducing 
symptoms in three of the four categories (as established 
by Abraham) of PMS20. 
Calcium 
Calcium carbonate should be recommended as first-line 
therapy for women with mild-to moderate PMS. Studies 
found calcium supplementation to significantly reduce 
symptoms of PMS compared to placebo20. Calcium is an 
essential mineral that activates a wide range of 
intracellular and extracellular responses including muscle 
contraction, nerve conduction, glycogen metabolism, 
cellular differentiation and immune function. Calcium 
fluxes across cell and plasma membranes and plays a vital 
role in the secondary messenger system allowing 
hormone and neurotransmitter release 21. Calcium 
significantly decreases pain and water retention during 
the luteal and menstrual phase. Those on a high calcium 
(1200 mg) diet have fewer premenstrual symptoms 
related to mood, concentration and behaviour while a 
low manganese diet (1 mg as opposed to 5.6 mg) seemed 
to correlate with an increase in premenstrual symptoms.  
Vitamin D is essential for the absorption of calcium. 
Vitamin A 
It is helpful for the treatment of PMS, particularly for 
premenstrual headaches. Dose as low as 40,000 IU daily 
over a period of years may be toxic 22. Since recent 
evidence suggests that administering more than 10,000 
IU of supplemental vitamin A per day may increase the 
risk of teratogenicity, until more is known, dosages above 
10,000 IU per day should be avoided in all women 
capable of conception 23, 24. 
 
 
Zinc 
Zinc may be important, as it influences the binding of 
progesterone to human endometrium. Zinc is also 
involved with B6 in the synthesis of Gama amino butyric 
acid (GABA) and is necessary for the formation of 
Prostaglandin E1(PGE1) from linoleic acid25.Furthermore, 
zinc is necessary for the mobilization of vitamin A from 
the liver, so supplementation may decrease the necessary 
therapeutic dose of vitamin A . At doses of    50 mg daily, 
zinc may inhibit prolactin levels, an elevation of which 
may result in depressed progesterone 26. 
Flavonoids 
One hundred sixty-five women were treated with 
Endotelon, a standardized grape seed oligomeric 
proanthocyanidin (OPC). Significant improvement was 
noted with the use of flavonoids. After two cycles, there 
was 60.8% improvement and after four cycles, a 78.8% 
improvement in abdominal swelling, mammary 
symptoms, pelvic pain27, 28. Flavonoids such as apigenin 
and quercetin inhibit the synthesis of human oestrogen in 
vitro and may do so in vivo by competing with oestrogen 
substrates29. 
Pharmacological treatments for PMS 
Hormonal interventions 
Long-acting gonadotropin-releasing hormone (GnRH) 
agonists are effective but results in medical menopause 
with its accompanying symptoms, which leads women at 
risk for osteoporosis30. Approximately 60% to 70% of 
women with PMDD respond to leuprolide (a GnRH 
agonist), but it is difficult to predict who will respond; 
daily mood self-ratings of sadness, anxiety, and irritability 
predict a positive response to leuprolide with high 
probability32, 33. Side effects of GnRH agonists (hot flashes, 
night sweats, vaginal dryness, etc.) can be tempered by 
“adding back” some oestrogen with a hormonal agent 
with progestational activity to reduce the risks of 
unopposed oestrogen (i.e., endometrial hyperplasia) 34. 
Antidepressants 
Antidepressants effectively ameliorate affective and 
physical symptoms and improve quality of life and 
psychosocial function in patients with PMS and PMDD. 
These include:  Tricyclic antidepressants such as 
clomipramine, SSRIs, citalopram, escitalopram, fluoxetine, 
paroxetine, and sertraline, serotonin-noradrenergic 
reuptake inhibitor venlafaxine35. Dosing antidepressants 
only in the luteal phase (taking the antidepressant from 
ovulation onset to the start of menses) is an effective 
treatment strategy. All serotonergic antidepressants 
which have been studied, found to be more effective than 
placebo with an average response rate of approximately 
60% in double blind placebo control trials. Selective 
serotonin reuptake inhibitors can be considered as first-
line therapy for women with severe affective symptoms 
and for women with milder symptoms who have failed to 
respond to other therapies.36, 37. Nonserotonergic 
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antidepressants such as maprotiline and desipramine 
have been less helpful in comparison with SSRIs. SSRIs 
given in the half of the cycle can be as effective as 
continuous daily dosing. In the case of citalopram, half-
cycle dosing was better than continuous dosing. Women 
with PMS may have decreased serotonergic activity 
across the menstrual cycle as a trait, and during the 
lutealphase.Other medications include anxiolytics like 
Alprazolam & Bromocriptine for decreasing breast 
tenderness.An extensive review by Andersch, which 
analyzed 14 randomized controlled trials until 1982, 
found no improvement in general PMS symptoms 
compared with placebo. One exception was severe cyclic 
mastalgia, for which bromocriptine might be effective38,39. 
High-dose oestrogen as transdermal patches or 
subcutaneous implants to inhibit ovulation is effective, 
but because of the risks of unopposed oestrogen, a 
progestin would be needed. Risks of oestrogen therapy 
(alone and in combination with progestins) include 
increased risk of endometrial cancer, coronary heart 
disease, breast cancer, stroke, and pulmonary 
embolism40, 41. Danazol, a synthetic androgen and 
gonadotropin inhibitor, effectively block ovulation, but 
cause side effects include hirsutism and possible 
teratogenicity42. The use of combined oral contraceptives 
(oestrogen and progestin) is common. A combination oral 
contraceptive, drospirenone/ethinyl estradiol, is FDA-
approved for treating PMDD in women seeking hormonal 
contraception because it has shown efficacy compared 
with placebo, with reported improvements in perceived 
productivity, social activities, and interpersonal 
relationships 43, 44. 
Spironolactone 
Spironolactone, the potassium-sparing diuretic with anti-
androgenic effects, significantly improved symptoms of 
breast tenderness, bloating, weight gain, and depressed 
mood compared with placebo, and physicians may 
consider it as a pharmacologic option for treating PMS 
symptoms.45, 46. In double blind cross over Randomized 
Control Trial using spironolactone resulted in 
improvement in mood for 80% of treated cycles 46. 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
In Double-blind crossover RCT with 39 participants shows 
that Mefenamic acid improved general symptoms such as 
tension, irritability, depression and pain where as  Mire et 
al studies states that Significant improvement in fatigue 
(P < 0.001), general malaise (P < 0.001),  headache (P < 
0.005), irritability (P < 0.01), and depressed mood (P < 
0.01). No improvement in breast symptoms, swelling 47.  
Surgical treatment, principally hysterectomy plus bilateral 
oophorectomy, is controversial because it is irreversible 
and associated with significant risks. Surgery may be 
considered in severely affected patients who failed to 
respond to other therapies and also have significant 
gynaecologic problems for which surgery would be 
appropriate.  
Symptoms Treatment 
Swelling  Spironolactone 100mg/d po; Start at midcycle 
(days 12 to 16), magnesium (360mg/day) 
Pain Mefenamic acid (500mg tid) start at 16th day 
in cycle or start at PMS symptoms 
Perimenstrual  
Symptoms 
Treat with hormonal therapies, Estradiol 
patch(0.1 or 0.2 mcg patches for 2 weeks 
+medroxyprogesterone acetate(5mg from 
17th to 25th day) 
Affective 
symptoms 
Fluoxetine(20 mg daily po) 
Sertraline (50 mg daily po) 
Fluvoxamine (50 mg daily po) 
Mastalgia Treat with primrose oil three to four times 
daily 
General Vitamin B6(50 mg once or twice daily) 
Vitamin E(400 IU Daily) 
Surgical bilateral ophorectomy is effective but extremely 
invasive, especially in younger women in whom removal 
of ovaries generally is inadvisable. Patients should receive 
a trial of a GnRH agonist before a surgical intervention, 
because oophorectomy may not reduce symptoms and is 
irreversible. Oophorectomy also would require hormone 
replacement therapy. 
CONCLUSION  
PMS symptoms can have debilitating effects on women's 
quality of life and work production. A well developed 
education program will help in increasing knowledge and 
decreasing the severity of symptoms of PMS. Clinical 
Pharmacists can improve the recognition and 
management of these common conditions by providing 
patient education on premenstrual symptoms and 
counselling women on lifestyle interventions and 
pharmacotherapy to relieve their discomfort.  
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